Keros Therapeutics Announces Final Results of Tender Offer

Core Points - Keros Therapeutics, Inc. announced the final results of its cash tender offer to repurchase up to 10,950,165 shares of common stock at a fixed price of $17.75 per share, totaling approximately $194.4 million [1][3] - The tender offer expired on November 18, 2025, and was part of a larger $375 million capital return program [1] - A total of 17,712,262 shares were validly tendered, leading to a pro rata acceptance of shares at a final proration factor of approximately 62.30% [2][3] Company Overview - Keros is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins [6] - The company is recognized for its understanding of TGF-ß proteins, which regulate the growth and maintenance of various tissues [6] - Keros' lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its advanced candidate, elritercept, addresses cytopenias in patients with myelodysplastic syndrome and myelofibrosis [6]